Tower Research Capital (TRC)’s OptimizeRx OPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding OPRX
WCA
RA
PHP
VCM
KCM
RHJA
Tower Research Capital (TRC)'s OPRX Position: Q1 2026 in Review
Tower Research Capital (TRC) reduced its OptimizeRx (OPRX) stake by 15% in Q1 2026, selling an estimated $2.95K and leaving 1,829 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3838.
Tower Research Capital (TRC) first reported a position in OPRX in Q3 2018 and has held it in 31 quarters since. The position peaked at $347K in Q4 2022. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.
- Tower Research Capital (TRC) held 1,829 shares of OptimizeRx worth $11.5K as of Q1 2026.
- Tower Research Capital (TRC) sold 318 OptimizeRx shares in Q1 2026, an estimated $2.95K.
- OptimizeRx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3838 holding.
- Tower Research Capital (TRC) first reported a position in OptimizeRx in Q3 2018 and has held it in 31 quarters since.
- Tower Research Capital (TRC)'s OptimizeRx position peaked at $347K in Q4 2022.
- 127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.